American Journal of Cardiology
Volume 106, Issue 7 , Pages 911-916 , 1 October 2010

Risk of All-Cause Mortality, Recurrent Myocardial Infarction, and Heart Failure Hospitalization Associated With Smoking Status Following Myocardial Infarction With Left Ventricular Dysfunction

  • Amil M. Shah, MD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 978-273-9053; fax: 617-582-6027
    • ,
  • Marc A. Pfeffer, MD, PhD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • L. Howard Hartley, MD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Lemuel A. Moyé, MD, PhD

      Affiliations

    • University of Texas School of Public Health, Health Sciences Center at Houston, Houston, Texas
    • ,
  • Bernard J. Gersh, MD, MB, ChB, DPhil

      Affiliations

    • Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota
    • ,
  • John D. Rutherford, MD

      Affiliations

    • Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas
    • ,
  • Gervasio A. Lamas, MD

      Affiliations

    • Mt. Sinai Medical Center and Columbia University, Miami Beach, Florida
    • ,
  • Jean L. Rouleau, MD

      Affiliations

    • Department of Medicine, University of Montréal, Montreal, Quebec, Canada
    • ,
  • Eugene Braunwald, MD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Scott D. Solomon, MD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts

Received 15 April 2010 ,Revised 11 May 2010 ,Accepted 11 May 2010.

References 

  1. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290:86–97
  2. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. Hawkins CM Effect of captopril on mortalitymorbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med. 1992;327:669–677
  3. Moye LA, Pfeffer MA, Braunwald E. Rationale, design and baseline characteristics of the Survival and Ventricular Enlargement trial. Am J Cardiol. 1991;68(suppl):70D–79D
  4. Rosenberg L, Kaufman DW, Helmrich SP, Shapiro S. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med. 1985;313:1511–1514
  5. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med. 1990;322:213–217
  6. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–952
  7. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003
  8. Anderson RE, Pfeffer MA, Thune JJ, McMurray JJV, Califf RM, Velazquez E, et al. High-risk myocardial infarction in the young: the Valsartan In Acute Myocardial Infarction (VALIANT) trial. Am Heart J. 2008;155:706–711
  9. Edwards R. The problem of tobacco smoking. BMJ. 2004;328:217–219
  10. Mahonen MS, McElduff P, Dobson AJ, Kuulasmaa KA, Evans AE. Current smoking and the risk of non-fatal myocardial infarction in the WHO MONICA Project populations. Tob Control. 2004;13:244–250
  11. Kelly TL, Gilpin E, Ahnve S, Henning H, Ross J. Smoking status at the time of acute myocardial infarction and subsequent prognosis. Am Heart J. 1985;110:535–541
  12. Gottlieb S, Boyko V, Zahger D, Balkin J, Hod H, Pelled B, et al. Smoking and prognosis after acute myocardial infarction in the thrombolytic era (Israeli thrombolytic national survey). J Am Coll Cardiol. 1996;28:1506–1513
  13. Andrikopoulos GK, Richter DJ, Dilaveris PE, Pipilis A, Zaharoulis A, Gialafos JE, et al. In-hospital mortality of habitual cigarette smokers after acute myocardial infarction: the “smoker's paradox” in a countrywide study. Eur Heart J. 2001;22:776–784
  14. Rea TD, Heckbert SR, Kaplan RC, Smith NL, Lemaitre RN, Psaty BM. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med. 2002;137:494–500
  15. Gerber Y, Rosen LJ, Goldbourt U, Benyamini Y, Drory Y. Smoking status and long-term survival after first acute myocardial infarction: A population-based cohort study. J Am Coll Cardiol. 2009;54:2382–2387
  16. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet. 2001;357:1385–1390
  17. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  18. Rabinowitz BD, Thorp K, Huber GL, Abelmann WH. Acute hemodynamic effects of cigarette smoking in man assessed by systolic time intervals and echocardiography. Circulation. 1979;60:752–760
  19. Laustiola KE, Lassila R, Nurmi A-K. Enhanced activation of the renin-angiotensin-aldosterone system in chronic cigarette smokers: a study of monozygotic twin pairs discordant for smoking. Clin Pharmacol Ther. 1988;44:426–430
  20. Setoguchi S, Glynn RJ, Avorn J, Levin R, Winkelmayer WC. Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons ≥65 years of age. Am J Cardiol. 2007;100:1061–1067
  21. Setoguchi S, Glynn RJ, Avorn J, Mittleman MA, Levin R, Winkelmayer WC. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol. 2008;51:1247–1254
  22. Ludvig J, Miner B, Eisenberg MJ. Smoking cessation in patients with coronary artery disease. Am Heart J. 2005;149:565–572
  23. Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomized study. Eur Heart J. 2003;24:946–955
  24. Ockene I, Salmoirago-Blotcher E. Varenicline for smoking cessation in patients with coronary heart disease. Circulation. 2010;121:188–190
  25. Van Spall HGC, Chong A, Tu JV. Inpatient smoking-cessation counseling and all-cause mortality in patients with acute myocardial infarction. Am Heart J. 2007;154:213–220
  26. Nides M, Glover ED, Reus VI, Christen AG, Make BJ, Billing CB, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav. 2008;32:664–675
  27. Burling TA, Singleton EG, Bigelow GE, Baile WF, Gottlieb SH. Smoking following myocardial infarction: a critical review of the literature. Health Psychol. 1984;3:83–96

PII: S0002-9149(10)01121-5

doi: 10.1016/j.amjcard.2010.05.021

American Journal of Cardiology
Volume 106, Issue 7 , Pages 911-916 , 1 October 2010

Article Tools

* Image Usage & Resolution